In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI.
about
Advances in Engineered Liver Models for Investigating Drug-Induced Liver InjuryA New Structure-Activity Relationship (SAR) Model for Predicting Drug-Induced Liver Injury, Based on Statistical and Expert-Based Structural AlertsSystems biology for simulating patient physiology during the postgenomic era of medicineMechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid-Mediated DILIExploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury.Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis.An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters.Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicityIn silico model-based inference: an emerging approach for inverse problems in engineering better medicinesModeling drug- and chemical-induced hepatotoxicity with systems biology approaches.A multi-scale modeling framework for individualized, spatiotemporal prediction of drug effects and toxicological risk.A model qualification method for mechanistic physiological QSP models to support model-informed drug development.Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors.A mechanistic model of drug-induced liver injury AIDS the interpretation of elevated liver transaminase levels in a phase I clinical trial.Systems toxicology: from basic research to risk assessment.Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors.Systems pharmacology modeling: an approach to improving drug safety.Linking physiology to toxicity using DILIsym®, a mechanistic mathematical model of drug-induced liver injury.The application of engineered liver tissues for novel drug discovery.The Promise of New Technologies to Reduce, Refine, or Replace Animal Use while Reducing Risks of Drug Induced Liver Injury in Pharmaceutical Development.A novel approach for estimating ingested dose associated with paracetamol overdose.Characterizing the Effects of Race/Ethnicity on Acetaminophen Pharmacokinetics Using Physiologically Based Pharmacokinetic Modeling.MITOsym®: A Mechanistic, Mathematical Model of Hepatocellular Respiration and Bioenergetics.Setting Clinical Exposure Levels of Concern for Drug-Induced Liver Injury (DILI) Using Mechanistic in vitro Assays.Systems pharmacology modeling of drug-induced hyperbilirubinemia: Differentiating hepatotoxicity and inhibition of enzymes/transporters.Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym(®), a Mechanistic Model of Drug-Induced Liver Injury.In Vitro Drug-Induced Liver Injury Prediction: Criteria Optimization of Efflux Transporter IC50 and Physicochemical Properties.Bridging the Data Gap From Toxicity Testing to Chemical Safety Assessment Through Computational Modeling
P2860
Q28077505-97163F5F-83C7-40F4-9CCC-E2A7D43DBBD4Q28820944-E59DE803-627C-4014-8F2D-EDDD5107C4E3Q33689713-824A7952-5FD0-4F0E-AD0E-528536865220Q33994553-90CCB015-40F1-49AB-A37E-51354D901FA7Q34471194-FF7CF1C2-E7F3-4FA3-8700-EAF7465FF85FQ34810094-FEA845F2-CE59-4EC5-9DBC-AD60C092E593Q35206374-ABF231AE-6B20-4554-B1A4-6893ED71A6ABQ35781894-E6EFAFCB-1E10-4245-A47C-7F8356396974Q35984945-CB1D99E8-992E-4F37-B4CE-EC7EB33473B3Q36466007-CCA3A33E-0A4B-4925-A23C-1B7A9ECCF4FCQ36550939-F0CC39CB-B2B2-40BF-8A7A-5722B457B695Q36600060-C16ED155-81B7-4DE4-AE23-2569F0E52496Q37564187-A05D0ED7-7510-4FDF-91EA-FAAF56A4C17DQ37620390-AE929AE7-5618-4FED-B020-D5C5D7063C81Q37661327-F8CF5021-B028-40A8-AE07-2B87472EB0DCQ38095989-A42EAB83-7921-499D-A703-79EC0BE14981Q38153621-E0AB2EE7-0DAC-4390-BA6A-7839B675CAF4Q38161471-10D87B38-BB68-4060-BEAF-0508ABFBD3EBQ38404573-51FE4DC2-6009-4EBF-8895-953C62695B1FQ38774776-8358EAA2-9108-49FB-B909-806514687133Q39220833-9B001073-37FF-469D-9541-42E479258C6CQ39923957-F5E26E7A-3C91-4C63-8EC2-4314C131C729Q40376380-41211CB1-818D-4C3E-A7CA-B74E1CE43B0BQ40701934-F9B12A8F-5340-4F92-948C-33C819272A2CQ42091235-931C3A7D-92AE-4410-BB97-8BCAAA312AA3Q43066578-C90119ED-5EC5-4084-AE56-45CF43186A18Q51075204-2086E274-665A-45DC-B565-65B578F68B65Q58750452-94564F4A-91B1-43C2-A41B-155A50911084
P2860
In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
In vitro to in vivo extrapolat ...... c, mathematical model of DILI.
@en
In vitro to in vivo extrapolat ...... c, mathematical model of DILI.
@nl
type
label
In vitro to in vivo extrapolat ...... c, mathematical model of DILI.
@en
In vitro to in vivo extrapolat ...... c, mathematical model of DILI.
@nl
prefLabel
In vitro to in vivo extrapolat ...... c, mathematical model of DILI.
@en
In vitro to in vivo extrapolat ...... c, mathematical model of DILI.
@nl
P2093
P2860
P1476
In vitro to in vivo extrapolat ...... c, mathematical model of DILI.
@en
P2093
Brett A Howell
Harvey J Clewell
Jeffrey L Woodhead
Paul B Watkins
Rukmini Kumar
Scott Q Siler
Yuching Yang
P2860
P2888
P304
P356
10.1007/S10928-012-9266-0
P577
2012-08-09T00:00:00Z